Biogen

Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Reuters
Biogen
Eisai
Japan
Leqembi
Alzheimer's disease
Flag link:
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Alzheimer's disease
Eli Lilly
Biogen
Eisai
Leqembi
donanemab
Flag link:
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Fierce Biotech
SAGE Therapeutics
layoffs
Biogen
major depressive disorcer
zuranolone
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
BioSpace
Biogen
Sandoz
FDA
biosimilars
MS
multiple sclerosis
Tysabri
Flag link:
Brii Biosciences aims to come up big where Sage and Biogen fell short
Brii Biosciences aims to come up big where Sage and Biogen fell short
Pharma Voice
Brii Biosciences
depression
SAGE Therapeutics
Biogen
BRII-296
postpartum depression
Flag link:
Biogen kicks off 1,000 layoffs as part of CEO Viehbacher’s ‘complete redesign’
Biogen kicks off 1,000 layoffs as part of CEO Viehbacher’s ‘complete redesign’
Fierce Pharma
Biogen
layoffs
restructuring
Flag link:
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
Fierce Pharma
Biogen
Reata Pharmaceuticals
M&A
Skyclarys
Friedreich’s ataxia
Flag link:
New Alzheimer’s drug raises hopes — along with questions
New Alzheimer’s drug raises hopes — along with questions
Medical Marketing and Media
FDA
Alzheimer's disease
Eisai
Biogen
Leqembi
Flag link:
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Flag link:
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
Motley Fool
Biogen
Reata Pharmaceuticals
M&A
Skyclarys
Flag link:
Biogen, Sage's postpartum depression approval overshadowed by larger rejection
Biogen, Sage's postpartum depression approval overshadowed by larger rejection
Fierce Pharma
SAGE Therapeutics
Biogen
FDA
Zurzuvae
postpartum depression
major depressive disorder
Flag link:
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Biogen
SAGE Therapeutics
FDA
Zurzuvae
postpartum depression
major depressive disorder
zuranolone
Flag link:
Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports
Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports
Fierce Pharma
Biogen
biosimilars
M&A
Samsung Bioepis
Flag link:
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
Medical Marketing and Media
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Motley Fool
Biogen
Reata Pharmaceuticals
M&A
Flag link:
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
Fierce Pharma
FDA
Biogen
Aduhelm
Alzheimer's disease
advisory committees
drug approvals
Flag link:
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Flag link:
Go or no go? Biogen and Astellas head towards key PDUFAs
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
Flag link:
Biogen to acquire rare disease drugmaker Reata for $7.3B
Biogen to acquire rare disease drugmaker Reata for $7.3B
BioPharma Dive
Biogen
Reata Pharmaceuticals
M&A
Friedreich's Ataxia
Flag link:

Pages